Zimmer Biomet: Can Its Surge in Knees and Hips Spark a Major Market Comeback?

The third quarter of 2025 saw Zimmer Biomet deliver a mixed performance, demonstrating both strengths and areas of concern. The company achieved a sales growth of 5% on an organic constant currency basis, highlighted by a significant improvement in its U.S. business, which increased by 5.6%. Key product lines such as the Persona OsseoTi Cementless Total Knee and the Oxford Partial Cementless Knee showed strong adoption, contributing to an overarching success in the knee segment, which grew 5.3%. Moreover, the U.S. reported robust growth driven by strong performances in their S.E.T. business and technology spheres, notably achieving their best robotics sales quarter in over a year. Despite these positive aspects, Zimmer Biomet faced challenges, primarily stemming from unexpected market weaknesses. Specific headwinds were noted in Eastern Europe, Latin America, and non-core segments like restorative therapies, which collectively impacted growth by 120 basis points.